Targeted Oncology Staff

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal patient selection for CLL.

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic renal cell carcinoma.

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.

In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key discussions on trial access gaps.

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers.

During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.

This week: FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and TNBC research aims for safer treatments.

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination regimens for hepatocellular carcinoma.

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE trial.

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with non–small cell lung cancer.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with high PD-L1.

During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in hepatocellular carcinoma.

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the KRAS-mutated non–small cell lung cancer population.

Discover the latest breakthroughs in oncology, including pivotal FDA decisions, promising therapies, and new treatment options for multiple myeloma and ovarian cancer.

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid tumor management.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.

During a live event, Nelson J. Chao, MD, asked participants how they employ the currently approved treatments for chronic GVHD.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma.

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer.

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed or high-risk lymphoma.